Reading Time: 4 minutesHi there! My name is Libby and I have recently joined the MND Association’s Research Information team alongside Katy. We’ll be working together, as Research
Tag: biomarkers

Reading Time: 6 minutesLast month we hosted our annual event for early career researchers (ECRs) in the UK. MND EnCouRage UK is a two day event which aims

Developing a potential microRNA blood test for ALS diagnosis
Reading Time: 4 minutesI’m Hannah, a PhD student from the University of Nottingham, and a Communications Ambassador for the 34th International Symposium on ALS/MND that took place in

Symposium Preview: Meet the ALS/FTD Plenary Speakers…Part 1
Reading Time: 5 minutesEvery year, the team works hard to build on the previous year’s success. This year we are excited to include a series of three ALS-FTD joint sessions, in collaboration with the International Society for Frontotemporal Dementias, in the programme.
Some people with ALS, the most common form of MND, also develop a form of dementia known as frontotemporal dementia (FTD). FTD is a group of disorders where the nerve cells in two sets of lobes (frontal and temporal) in the brain are damaged. In a similar way to how motor neurones break down in MND and cause loss of function in muscles, the damage to the nerve cells in FTD causes the connections between parts of the brain to break down. As more cells become damaged and die this can lead to symptoms such as problems with memory, thinking or language, changes in mood, emotions and behaviour.

Highlights from MND EnCouRage UK 2023
Reading Time: 5 minutesHi everyone! My name’s Katie and I recently joined the Association as a Supporter Information Officer. My role offers me a unique perspective as I

Reading Time: 4 minutesA recent paper published in Brain Communications has identified several lipid (fat-like) molecules that are elevated in MND, specifically amyotrophic lateral sclerosis (ALS) which is

Reading Time: 4 minutesDiagnosing disease faster, accurately predicting disease progression, assessing the ability of a new drug to reach its target – I think we’d all agree that

Reading Time: 4 minutesThis is blog number 15 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond

32nd International Symposium: meet our plenary speakers (part 2)
Reading Time: 7 minutesThis is blog number 13 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond

Reading Time: 9 minutesA paper arising from research carried out at the University of Sheffield as part of the AMBRoSIA biobank, and in collaboration with the international Project